Life sciences firm raises £16m to fund oncology research
The oversubscribed placing, comprising 25,396,806 new ordinary shares at an issue price of 63 pence per share, drew strong support from institutional and high net worth investors.
The funds will provide additional working capital to progress Wetherby-based Avacta’s expanding R&D pipeline into the second half of 2026, including advancement of the faridoxorubicin (A... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
